Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meglumine antimonate intralesional versus systemic treatment for cutaneous leishmaniasis in Brazil
RBR-6mk5n4Phase 3Recruiting
- Sponsor
- Evandro Chagas National Institute of Infectology
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) and American tegumentary leishmaniasis (ATL) (2 arms), sponsored by Evandro Chagas National Institute of Infectology. Started Dec 2017; status: recruiting.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)American tegumentary leishmaniasis (ATL)
Beyond the preview
Go deeper on RBR-6mk5n4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6mk5n4.